Fulvestrant monotherapy is not listed under “Preferred Regimens” but is classified as an “Other Recommended Regimen” for first- and/or subsequent-line therapy in HR+/HER2- advanced breast cancer, according to current guidelines [2]. The gene discussed is ERBB2; the disease is breast cancer.